CompletedPhase 3

Use of Pentoxifylline in Human T-lymphotropic Virus Type-1 (HTLV-1) Diseases

Brazil48 participantsStarted 2009-09

Plain-language summary

In this study the investigators are going to evaluate the efficacy pentoxifyline in HTLV-1 patients with neurological diseases: HAM/TSP or neurogenic bladder. In some laboratory experiments the investigators observed that this drug had the capacity to reduce the immune response in HTLV-1 infected cells. Since the exacerbated immune response is know to cause neurological disease in patients with HTLV-1 the investigators hope that pentoxifyline can alleviate symptoms and delay the progress of HAM/TSP in patients.

Who can participate

Age range18 Years – 80 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Age ≥ 18 and ≤ 80 years; * Confirmed HTLV-1 infection with Western Blot analysis; * HAM/TSP diagnosed patients according to the WHO * Patients with HTLV-1 and neurogenic bladder diagnosed by clinical and urodynamic study * Disease duration \< 5 years Exclusion Criteria: * Neurological diseases with functional limitations. * Co-infection with Hepatitis B or C, Syphilis, Chagas Disease or HIV * Use of immunossupressive drugs * Immune disease * Pregnancy

What they're measuring

Functional neurological capacity

Timeframe: 60 days

Trial details

NCT IDNCT01472263

SponsorHospital Universitário Professor Edgard Santos

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2012-09

View on ClinicalTrials.gov More HTLV-1 trials